Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Guards Viagra Sales, Moves Against Tainted Supplements

This article was originally published in The Tan Sheet

Executive Summary

A Pfizer study that finds 81% of sexual performance products claiming to be natural have undeclared pharmaceuticals could pressure FDA to increase enforcement and Congress to boost funding. The firm also launches online sales of Viagra to combat sales of counterfeit erectile dysfunction drugs.

You may also be interested in...



Top Supplement Stories 2013: POM Saga, Spiked Products, GMPs

Experts’ predictions for tighter GMP enforcement and the federal government shutdown’s effect on industries regulated by CFSAN joined the POM-FTC litigation and Pfizer’s work to identify bad actors making ED-spiked supplements as top supplement sector stories in “The Tan Sheet” during 2013.

Top Supplement Stories 2013: POM Saga, Spiked Products, GMPs

Experts’ predictions for tighter GMP enforcement and the federal government shutdown’s effect on industries regulated by CFSAN joined the POM-FTC litigation and Pfizer’s work to identify bad actors making ED-spiked supplements as top supplement sector stories in “The Tan Sheet” during 2013.

Pfizer Tracking Spiked Supplements With FDA, Enforcement Agencies

Pfizer helps law enforcement and FDA root out marketers of tainted supplements through undercover purchases of products the firm tests. Pfizer’s security team also gathers evidence for criminal enforcement and regulatory actions, but does not bring civil actions against offenders.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel